Profile data is unavailable for this security.
About the company
Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.
- Revenue in HKD (TTM)1.18bn
- Net income in HKD618.05m
- Incorporated2002
- Employees1.18k
- LocationDawnrays Pharmaceutical (Holdings) LtdUnits 3001-02, 30/F, CNT Tower, Wanchai Hong KongHKG
- Phone+852 21119708
- Fax+852 21119870
- Websitehttps://www.dawnrays.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hbm Holdings Ltd | 561.11m | 165.51m | 1.02bn | 158.00 | 5.91 | 1.02 | 5.21 | 1.82 | 0.225 | 0.225 | 0.7611 | 1.30 | 0.3258 | 3.96 | 16.67 | 3,170,091.00 | 9.59 | -54.61 | 13.25 | -66.04 | 95.57 | 97.81 | 29.42 | -400.28 | 3.44 | 8.14 | 0.3502 | -- | 120.13 | 127.06 | 116.61 | -- | -12.62 | -- |
Jacobson Pharma Corporation Ltd | 1.47bn | 210.24m | 1.26bn | 1.72k | 5.76 | 0.5259 | 3.58 | 0.8585 | 0.1095 | 0.1391 | 0.7644 | 1.20 | 0.3311 | 2.47 | 6.37 | 851,885.10 | 4.74 | 4.30 | 5.76 | 5.57 | 42.27 | 41.25 | 14.32 | 13.73 | 1.73 | 5.33 | 0.2382 | 40.62 | 15.79 | -0.1401 | 1.31 | -3.05 | 24.06 | 4.10 |
Ascletis Pharma Inc | 11.07m | -283.69m | 1.33bn | 219.00 | -- | 0.5713 | -- | 120.41 | -0.2733 | -0.2733 | 0.0107 | 2.36 | 0.0041 | 1.34 | 3.58 | 50,568.44 | -10.47 | -6.43 | -10.85 | -6.64 | -125.17 | 35.67 | -2,561.69 | -243.38 | 24.31 | -- | 0.004 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
SinoMab Bioscience Ltd | 2.22m | -219.12m | 1.50bn | 214.00 | -- | 4.92 | -- | 672.63 | -0.2103 | -0.2103 | 0.0021 | 0.2784 | 0.0023 | -- | -- | 10,342.69 | -22.83 | -24.62 | -29.11 | -27.72 | 26.80 | -- | -9,853.75 | -4,451.74 | -- | -81.79 | 0.6339 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
Essex Bio-Technology Ltd | 1.62bn | 262.89m | 1.65bn | 1.46k | 6.45 | 0.8166 | 5.18 | 1.02 | 0.4499 | 0.4499 | 2.73 | 3.55 | 0.5587 | 2.62 | 2.73 | 1,093,064.00 | 9.07 | 11.20 | 12.10 | 14.73 | 89.78 | 86.01 | 16.24 | 19.77 | 1.61 | -- | 0.1397 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
Dawnrays Pharmaceutical (Holdings) Ltd | 1.18bn | 618.05m | 1.86bn | 1.18k | 3.01 | 0.5187 | 2.67 | 1.57 | 0.4114 | 0.4114 | 0.7882 | 2.39 | 0.2838 | 2.05 | 6.17 | 1,035,799.00 | 14.74 | 9.89 | 17.79 | 12.49 | 56.58 | 56.69 | 51.92 | 27.89 | 3.04 | -- | 0.0544 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
Cryofocus Medtech Shanghai Co Ltd | 45.56m | -116.62m | 1.91bn | 370.00 | -- | 14.77 | -- | 41.93 | -0.4877 | -0.4877 | 0.1906 | 0.5408 | 0.1881 | 0.418 | 4,369.58 | 116,227.70 | -51.79 | -- | -66.30 | -- | 76.35 | -- | -275.28 | -- | 2.06 | -80.68 | 0.2303 | -- | 50.83 | -- | 13.13 | -- | -- | -- |
VIVA Biotech Holdings | 2.19bn | -349.03k | 2.09bn | 2.04k | -- | 0.4996 | 8.17 | 0.9535 | -0.0055 | -0.0055 | 1.07 | 1.94 | 0.2603 | 5.26 | 5.18 | 1,054,354.00 | 0.4017 | -1.39 | 0.5601 | -1.68 | 33.66 | 34.81 | 1.54 | -5.44 | 1.46 | 3.19 | 0.2884 | -- | -9.42 | 59.31 | 78.03 | -- | 31.98 | -- |
Golden Throat Holdings Group Co Ltd | 1.10bn | 287.80m | 2.33bn | 860.00 | 8.09 | 1.65 | 7.05 | 2.11 | 0.3893 | 0.3893 | 1.49 | 1.90 | 0.4994 | 3.23 | 4.07 | 1,270,917.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
Data as of Oct 10 2024. Currency figures normalised to Dawnrays Pharmaceutical (Holdings) Ltd's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 94.20m | 6.28% |
UBS Asset Management (Hong Kong) Ltd.as of 30 Apr 2024 | 37.04m | 2.47% |
Dimensional Fund Advisors LPas of 03 Jul 2024 | 10.98m | 0.73% |
Fidelity Investments Canada ULCas of 30 Jun 2024 | 7.79m | 0.52% |
CATAM Asset Management AGas of 31 Mar 2021 | 3.23m | 0.22% |
Strategic Advisers LLCas of 30 Jun 2024 | 2.41m | 0.16% |
Dimensional Fund Advisors Ltd.as of 31 May 2024 | 713.60k | 0.05% |
DFA Australia Ltd.as of 30 Jun 2024 | 221.98k | 0.02% |
Acadian Asset Management LLCas of 30 Jun 2024 | 150.04k | 0.01% |
FIL Investments Internationalas of 31 Dec 2023 | 32.43k | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.